{"id":55543,"date":"2025-07-30T08:43:02","date_gmt":"2025-07-30T08:43:02","guid":{"rendered":"https:\/\/ibima.eu\/estudio-de-fase-3-aleatorizado-abierto-multicentrico-de-arv-471-pf-07850327-frente-a-fulvestrant-en-participantes-con-cancer-de-mama-avanzado-con-receptores-estrogenicos-sin-mutacion-del-gen-her\/"},"modified":"2025-07-30T08:43:02","modified_gmt":"2025-07-30T08:43:02","slug":"estudio-de-fase-3-aleatorizado-abierto-multicentrico-de-arv-471-pf-07850327-frente-a-fulvestrant-en-participantes-con-cancer-de-mama-avanzado-con-receptores-estrogenicos-sin-mutacion-del-gen-her","status":"publish","type":"post","link":"https:\/\/ibima.eu\/es\/estudio-de-fase-3-aleatorizado-abierto-multicentrico-de-arv-471-pf-07850327-frente-a-fulvestrant-en-participantes-con-cancer-de-mama-avanzado-con-receptores-estrogenicos-sin-mutacion-del-gen-her\/","title":{"rendered":"Estudio de fase 3, aleatorizado, abierto, multic\u00e9ntrico de ARV-471 (PF-07850327) frente a Fulvestrant en participantes con c\u00e1ncer de mama avanzado con receptores estrog\u00e9nicos, sin mutaci\u00f3n del gen HER2 cuya enfermedad haya progresado despu\u00e9s de un tratamiento endocrino previo para la enfermedad avanzada (VERITAC 2)"},"content":{"rendered":"

FRANCISCO JAVIER PASCUAL LOPEZ – ENSAYO CLINICO CON MEDICAMENTOS – III – PFIZER INC.<\/p>\n","protected":false},"excerpt":{"rendered":"

FRANCISCO JAVIER PASCUAL LOPEZ – ENSAYO CLINICO CON MEDICAMENTOS – III – PFIZER INC.<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_et_pb_use_builder":"","_et_pb_old_content":"","_et_gb_content_width":"","footnotes":""},"categories":[2263,2295],"tags":[],"class_list":["post-55543","post","type-post","status-publish","format-standard","hentry","category-ensayos-clinicos","category-ensayos-clinicos-b-01-ensayos-clinicos"],"acf":[],"yoast_head":"\nEstudio de fase 3, aleatorizado, abierto, multic\u00e9ntrico de ARV-471 (PF-07850327) frente a Fulvestrant en participantes con c\u00e1ncer de mama avanzado con receptores estrog\u00e9nicos, sin mutaci\u00f3n del gen HER2 cuya enfermedad haya progresado despu\u00e9s de un tratamiento endocrino previo para la enfermedad avanzada (VERITAC 2) - Ibima<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ibima.eu\/es\/estudio-de-fase-3-aleatorizado-abierto-multicentrico-de-arv-471-pf-07850327-frente-a-fulvestrant-en-participantes-con-cancer-de-mama-avanzado-con-receptores-estrogenicos-sin-mutacion-del-gen-her\/\" \/>\n<meta property=\"og:locale\" content=\"es_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Estudio de fase 3, aleatorizado, abierto, multic\u00e9ntrico de ARV-471 (PF-07850327) frente a Fulvestrant en participantes con c\u00e1ncer de mama avanzado con receptores estrog\u00e9nicos, sin mutaci\u00f3n del gen HER2 cuya enfermedad haya progresado despu\u00e9s de un tratamiento endocrino previo para la enfermedad avanzada (VERITAC 2) - Ibima\" \/>\n<meta property=\"og:description\" content=\"FRANCISCO JAVIER PASCUAL LOPEZ – ENSAYO CLINICO CON MEDICAMENTOS – III – PFIZER INC.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ibima.eu\/es\/estudio-de-fase-3-aleatorizado-abierto-multicentrico-de-arv-471-pf-07850327-frente-a-fulvestrant-en-participantes-con-cancer-de-mama-avanzado-con-receptores-estrogenicos-sin-mutacion-del-gen-her\/\" \/>\n<meta property=\"og:site_name\" content=\"Ibima\" \/>\n<meta property=\"article:published_time\" content=\"2025-07-30T08:43:02+00:00\" \/>\n<meta name=\"author\" content=\"prodriguez\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"prodriguez\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/ibima.eu\\\/estudio-de-fase-3-aleatorizado-abierto-multicentrico-de-arv-471-pf-07850327-frente-a-fulvestrant-en-participantes-con-cancer-de-mama-avanzado-con-receptores-estrogenicos-sin-mutacion-del-gen-her\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/ibima.eu\\\/estudio-de-fase-3-aleatorizado-abierto-multicentrico-de-arv-471-pf-07850327-frente-a-fulvestrant-en-participantes-con-cancer-de-mama-avanzado-con-receptores-estrogenicos-sin-mutacion-del-gen-her\\\/\"},\"author\":{\"name\":\"prodriguez\",\"@id\":\"https:\\\/\\\/ibima.eu\\\/es\\\/#\\\/schema\\\/person\\\/40b410344dd5ad2315bb651e3fbfa635\"},\"headline\":\"Estudio de fase 3, aleatorizado, abierto, multic\u00e9ntrico de ARV-471 (PF-07850327) frente a Fulvestrant en participantes con c\u00e1ncer de mama avanzado con receptores estrog\u00e9nicos, sin mutaci\u00f3n del gen HER2 cuya enfermedad haya progresado despu\u00e9s de un tratamiento endocrino previo para la enfermedad avanzada (VERITAC 2)\",\"datePublished\":\"2025-07-30T08:43:02+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/ibima.eu\\\/estudio-de-fase-3-aleatorizado-abierto-multicentrico-de-arv-471-pf-07850327-frente-a-fulvestrant-en-participantes-con-cancer-de-mama-avanzado-con-receptores-estrogenicos-sin-mutacion-del-gen-her\\\/\"},\"wordCount\":61,\"commentCount\":0,\"articleSection\":[\"Ensayos Cl\u00ednicos\",\"Ensayos Cl\u00ednicos - B-01\"],\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/ibima.eu\\\/estudio-de-fase-3-aleatorizado-abierto-multicentrico-de-arv-471-pf-07850327-frente-a-fulvestrant-en-participantes-con-cancer-de-mama-avanzado-con-receptores-estrogenicos-sin-mutacion-del-gen-her\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/ibima.eu\\\/estudio-de-fase-3-aleatorizado-abierto-multicentrico-de-arv-471-pf-07850327-frente-a-fulvestrant-en-participantes-con-cancer-de-mama-avanzado-con-receptores-estrogenicos-sin-mutacion-del-gen-her\\\/\",\"url\":\"https:\\\/\\\/ibima.eu\\\/estudio-de-fase-3-aleatorizado-abierto-multicentrico-de-arv-471-pf-07850327-frente-a-fulvestrant-en-participantes-con-cancer-de-mama-avanzado-con-receptores-estrogenicos-sin-mutacion-del-gen-her\\\/\",\"name\":\"Estudio de fase 3, aleatorizado, abierto, multic\u00e9ntrico de ARV-471 (PF-07850327) frente a Fulvestrant en participantes con c\u00e1ncer de mama avanzado con receptores estrog\u00e9nicos, sin mutaci\u00f3n del gen HER2 cuya enfermedad haya progresado despu\u00e9s de un tratamiento endocrino previo para la enfermedad avanzada (VERITAC 2) - Ibima\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/ibima.eu\\\/es\\\/#website\"},\"datePublished\":\"2025-07-30T08:43:02+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/ibima.eu\\\/es\\\/#\\\/schema\\\/person\\\/40b410344dd5ad2315bb651e3fbfa635\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/ibima.eu\\\/estudio-de-fase-3-aleatorizado-abierto-multicentrico-de-arv-471-pf-07850327-frente-a-fulvestrant-en-participantes-con-cancer-de-mama-avanzado-con-receptores-estrogenicos-sin-mutacion-del-gen-her\\\/#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/ibima.eu\\\/estudio-de-fase-3-aleatorizado-abierto-multicentrico-de-arv-471-pf-07850327-frente-a-fulvestrant-en-participantes-con-cancer-de-mama-avanzado-con-receptores-estrogenicos-sin-mutacion-del-gen-her\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/ibima.eu\\\/estudio-de-fase-3-aleatorizado-abierto-multicentrico-de-arv-471-pf-07850327-frente-a-fulvestrant-en-participantes-con-cancer-de-mama-avanzado-con-receptores-estrogenicos-sin-mutacion-del-gen-her\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Portada\",\"item\":\"https:\\\/\\\/ibima.eu\\\/es\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Estudio de fase 3, aleatorizado, abierto, multic\u00e9ntrico de ARV-471 (PF-07850327) frente a Fulvestrant en participantes con c\u00e1ncer de mama avanzado con receptores estrog\u00e9nicos, sin mutaci\u00f3n del gen HER2 cuya enfermedad haya progresado despu\u00e9s de un tratamiento endocrino previo para la enfermedad avanzada (VERITAC 2)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/ibima.eu\\\/es\\\/#website\",\"url\":\"https:\\\/\\\/ibima.eu\\\/es\\\/\",\"name\":\"Ibima\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/ibima.eu\\\/es\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/ibima.eu\\\/es\\\/#\\\/schema\\\/person\\\/40b410344dd5ad2315bb651e3fbfa635\",\"name\":\"prodriguez\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/3e682b55f425f54644efd95284b890bfd6e129cc61dd791a9d4345ce1ed26791?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/3e682b55f425f54644efd95284b890bfd6e129cc61dd791a9d4345ce1ed26791?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/3e682b55f425f54644efd95284b890bfd6e129cc61dd791a9d4345ce1ed26791?s=96&d=mm&r=g\",\"caption\":\"prodriguez\"},\"sameAs\":[\"https:\\\/\\\/ibima.eu\"],\"url\":\"https:\\\/\\\/ibima.eu\\\/es\\\/author\\\/prodriguez\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Estudio de fase 3, aleatorizado, abierto, multic\u00e9ntrico de ARV-471 (PF-07850327) frente a Fulvestrant en participantes con c\u00e1ncer de mama avanzado con receptores estrog\u00e9nicos, sin mutaci\u00f3n del gen HER2 cuya enfermedad haya progresado despu\u00e9s de un tratamiento endocrino previo para la enfermedad avanzada (VERITAC 2) - Ibima","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ibima.eu\/es\/estudio-de-fase-3-aleatorizado-abierto-multicentrico-de-arv-471-pf-07850327-frente-a-fulvestrant-en-participantes-con-cancer-de-mama-avanzado-con-receptores-estrogenicos-sin-mutacion-del-gen-her\/","og_locale":"es_ES","og_type":"article","og_title":"Estudio de fase 3, aleatorizado, abierto, multic\u00e9ntrico de ARV-471 (PF-07850327) frente a Fulvestrant en participantes con c\u00e1ncer de mama avanzado con receptores estrog\u00e9nicos, sin mutaci\u00f3n del gen HER2 cuya enfermedad haya progresado despu\u00e9s de un tratamiento endocrino previo para la enfermedad avanzada (VERITAC 2) - Ibima","og_description":"FRANCISCO JAVIER PASCUAL LOPEZ – ENSAYO CLINICO CON MEDICAMENTOS – III – PFIZER INC.","og_url":"https:\/\/ibima.eu\/es\/estudio-de-fase-3-aleatorizado-abierto-multicentrico-de-arv-471-pf-07850327-frente-a-fulvestrant-en-participantes-con-cancer-de-mama-avanzado-con-receptores-estrogenicos-sin-mutacion-del-gen-her\/","og_site_name":"Ibima","article_published_time":"2025-07-30T08:43:02+00:00","author":"prodriguez","twitter_card":"summary_large_image","twitter_misc":{"Escrito por":"prodriguez"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/ibima.eu\/estudio-de-fase-3-aleatorizado-abierto-multicentrico-de-arv-471-pf-07850327-frente-a-fulvestrant-en-participantes-con-cancer-de-mama-avanzado-con-receptores-estrogenicos-sin-mutacion-del-gen-her\/#article","isPartOf":{"@id":"https:\/\/ibima.eu\/estudio-de-fase-3-aleatorizado-abierto-multicentrico-de-arv-471-pf-07850327-frente-a-fulvestrant-en-participantes-con-cancer-de-mama-avanzado-con-receptores-estrogenicos-sin-mutacion-del-gen-her\/"},"author":{"name":"prodriguez","@id":"https:\/\/ibima.eu\/es\/#\/schema\/person\/40b410344dd5ad2315bb651e3fbfa635"},"headline":"Estudio de fase 3, aleatorizado, abierto, multic\u00e9ntrico de ARV-471 (PF-07850327) frente a Fulvestrant en participantes con c\u00e1ncer de mama avanzado con receptores estrog\u00e9nicos, sin mutaci\u00f3n del gen HER2 cuya enfermedad haya progresado despu\u00e9s de un tratamiento endocrino previo para la enfermedad avanzada (VERITAC 2)","datePublished":"2025-07-30T08:43:02+00:00","mainEntityOfPage":{"@id":"https:\/\/ibima.eu\/estudio-de-fase-3-aleatorizado-abierto-multicentrico-de-arv-471-pf-07850327-frente-a-fulvestrant-en-participantes-con-cancer-de-mama-avanzado-con-receptores-estrogenicos-sin-mutacion-del-gen-her\/"},"wordCount":61,"commentCount":0,"articleSection":["Ensayos Cl\u00ednicos","Ensayos Cl\u00ednicos - B-01"],"inLanguage":"es","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/ibima.eu\/estudio-de-fase-3-aleatorizado-abierto-multicentrico-de-arv-471-pf-07850327-frente-a-fulvestrant-en-participantes-con-cancer-de-mama-avanzado-con-receptores-estrogenicos-sin-mutacion-del-gen-her\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/ibima.eu\/estudio-de-fase-3-aleatorizado-abierto-multicentrico-de-arv-471-pf-07850327-frente-a-fulvestrant-en-participantes-con-cancer-de-mama-avanzado-con-receptores-estrogenicos-sin-mutacion-del-gen-her\/","url":"https:\/\/ibima.eu\/estudio-de-fase-3-aleatorizado-abierto-multicentrico-de-arv-471-pf-07850327-frente-a-fulvestrant-en-participantes-con-cancer-de-mama-avanzado-con-receptores-estrogenicos-sin-mutacion-del-gen-her\/","name":"Estudio de fase 3, aleatorizado, abierto, multic\u00e9ntrico de ARV-471 (PF-07850327) frente a Fulvestrant en participantes con c\u00e1ncer de mama avanzado con receptores estrog\u00e9nicos, sin mutaci\u00f3n del gen HER2 cuya enfermedad haya progresado despu\u00e9s de un tratamiento endocrino previo para la enfermedad avanzada (VERITAC 2) - Ibima","isPartOf":{"@id":"https:\/\/ibima.eu\/es\/#website"},"datePublished":"2025-07-30T08:43:02+00:00","author":{"@id":"https:\/\/ibima.eu\/es\/#\/schema\/person\/40b410344dd5ad2315bb651e3fbfa635"},"breadcrumb":{"@id":"https:\/\/ibima.eu\/estudio-de-fase-3-aleatorizado-abierto-multicentrico-de-arv-471-pf-07850327-frente-a-fulvestrant-en-participantes-con-cancer-de-mama-avanzado-con-receptores-estrogenicos-sin-mutacion-del-gen-her\/#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ibima.eu\/estudio-de-fase-3-aleatorizado-abierto-multicentrico-de-arv-471-pf-07850327-frente-a-fulvestrant-en-participantes-con-cancer-de-mama-avanzado-con-receptores-estrogenicos-sin-mutacion-del-gen-her\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/ibima.eu\/estudio-de-fase-3-aleatorizado-abierto-multicentrico-de-arv-471-pf-07850327-frente-a-fulvestrant-en-participantes-con-cancer-de-mama-avanzado-con-receptores-estrogenicos-sin-mutacion-del-gen-her\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Portada","item":"https:\/\/ibima.eu\/es\/"},{"@type":"ListItem","position":2,"name":"Estudio de fase 3, aleatorizado, abierto, multic\u00e9ntrico de ARV-471 (PF-07850327) frente a Fulvestrant en participantes con c\u00e1ncer de mama avanzado con receptores estrog\u00e9nicos, sin mutaci\u00f3n del gen HER2 cuya enfermedad haya progresado despu\u00e9s de un tratamiento endocrino previo para la enfermedad avanzada (VERITAC 2)"}]},{"@type":"WebSite","@id":"https:\/\/ibima.eu\/es\/#website","url":"https:\/\/ibima.eu\/es\/","name":"Ibima","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/ibima.eu\/es\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es"},{"@type":"Person","@id":"https:\/\/ibima.eu\/es\/#\/schema\/person\/40b410344dd5ad2315bb651e3fbfa635","name":"prodriguez","image":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/secure.gravatar.com\/avatar\/3e682b55f425f54644efd95284b890bfd6e129cc61dd791a9d4345ce1ed26791?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/3e682b55f425f54644efd95284b890bfd6e129cc61dd791a9d4345ce1ed26791?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/3e682b55f425f54644efd95284b890bfd6e129cc61dd791a9d4345ce1ed26791?s=96&d=mm&r=g","caption":"prodriguez"},"sameAs":["https:\/\/ibima.eu"],"url":"https:\/\/ibima.eu\/es\/author\/prodriguez\/"}]}},"_links":{"self":[{"href":"https:\/\/ibima.eu\/es\/wp-json\/wp\/v2\/posts\/55543","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ibima.eu\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ibima.eu\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ibima.eu\/es\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/ibima.eu\/es\/wp-json\/wp\/v2\/comments?post=55543"}],"version-history":[{"count":0,"href":"https:\/\/ibima.eu\/es\/wp-json\/wp\/v2\/posts\/55543\/revisions"}],"wp:attachment":[{"href":"https:\/\/ibima.eu\/es\/wp-json\/wp\/v2\/media?parent=55543"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ibima.eu\/es\/wp-json\/wp\/v2\/categories?post=55543"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ibima.eu\/es\/wp-json\/wp\/v2\/tags?post=55543"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}